Just watched SI presentation at the Share Cafe Webinar. My key...

Just watched SI presentation at the Share Cafe Webinar. My key takeaways:

aGvHD:
* Coming quarter refiling
* Second half of year potential approval
* Small sales force as 50% of transplant centres in US
* Substantial reimbursement revenues (launch towards end of year)
* Japan seeing 30 - 40% adoption in market after 3 years
* Potency assay to predict clinical survival - new data shows this
* Very confident - resubmit data short order - review process 2 to 6 months
* Reiterated 9:1 ODAC vote - extra data requested around potency assays

IBD
* Current drugs on market cost about $60,000/year
* Update next couple of months further results
* Initial results outstanding

CLBP
* Most valuable opportunity - multi billion projected annual sales opportunity
* Second half of year to start CLBP trial

Interestingly didn't expand of CHF - intriguing - make of it what you wish. My thoughts probably because in discussions with FDA.

Mentioned extremely happy to have Dr Krause on board - asset for navigating first and subsequent products.

SI looks confident.

Good luck all!